This 5 page paper evaluates a case study submitted by a student. The case involves the marketing of a new drug where a firm has hidden vital information. An individual stumbles along the information and wonders what to do. The paper provides a solution to the dilemma as well as a counter argument. The paper also embraces ethics as it pertains to the sale of stock for this troubled company. Bibliography lists 3 sources.
Name of Research Paper File: RT13_SA350Col.rtf
Unformatted Sample Text from the Research Paper:
drug is used appropriately by the people, to properly reporting how the pharmaceutical firm is doing to the public. In a case study submitted by a student, it is learned
that certain data were suppressed when marketing a new drug. An employee caught in a situation as to whether or not to be a whistle blower is provided.
First, it seems safe to say that America is a corporate society premised on situational rather than absolute, ethics (Loeb, 2001). Because of this, one can see that there
are no right or wrong answers. Not all issues are black and white. At the same time, when evaluating a dilemma, most whistle blowers are not the primary players, but
rather people who have stumbled upon information not meant for their eyes. What should someone do in such a situation? The ethical dilemma presented really involves two issues, one of
which involves a stock offering, and the other involves the reporting of hidden information about a new drug, and a problem where both of these issues meet. II.
Case Study In a case study submitted by a student, a product development manager works for Goodhealth Drug Company. In going through a predecessors files, he discovers a
secret internal report about the companys new drug Colstop. This drug, introduced a bit over a year previously, is supposed to control cholesterol but it is found that the drug
only fully controls cholesterol in fifty percent of the cases. Yet, it is the only drug of the kind on the market and has been taken by more than
400, 000 people. It also accounted for a major upturn in sales and the firm is planning a significant secondary stock offering in three months time which would